HIPRA to Launch Modified COVID-19 Vaccine Against JN.1 Variant – Single Dose Format for Autumn Campaign

The biotechnology company HIPRA will launch a vaccine against COVID-19 adapted to the JN.1 version, according to new guidelines from health authorities that recommend updating vaccines for the next autumn vaccination campaign. HIPRA, thanks to the continuous monitoring of epidemiology, anticipated these recommendations and began the development of the new modified vaccine, manufacturing the first batches in its facilities in Spain to make sure that doses will be given to the people. The recombinant protein recombinant vaccine It will be available in a single dose format, which will simplify distribution and administration by health care workers, thus contributing to improving vaccination coverage rates.

The new vaccine was adapted from HYPER follow the recent recommendations from the Emergency Task Force (ETF) of the European Medicines Agency (EMA) and the WHO Technical Advisory Group (TAG-CO-VAC) on the composition of the COVID-19 vaccine for the upcoming autumn campaign (monovalent vaccines from JN. 1 ).

Studies are currently available in vivo showing that the HIPRA-modified COVID-19 vaccine produces high levels of neutralizing antibodies against this new family of variants, both in first vaccination plus booster doses. The new variation has been made possible due to the constant study of the new variants at the global level. In addition, the HIPRA team has been able to reduce the changeover times of their recombinant protein platform, which allowed this new change to be ready for the harvest campaign.

According to the EMA, between December 2023 and January of this year, the new version of the SARS-CoV-2, JN.1, is globally superior to the XBB variant family previously in circulation. JN.1 belongs to the BA.2.86 family of subvariable bomicronsHowever, the European Group points out that JN.1 is becoming a new family of modifications. Although currently authorized COVID-19 vaccines remain effective in preventing severe disease, immunity wanes over time and the circulating virus evolves into antigenically more susceptible variants. away from the composition of the vaccine. The EMA therefore recommends changing vaccines to ensure better protection against the current dominant variants and those that may arise from them.

You might also like…

Spain plans to get vaccinated with Hipra even though WHO recommends COVID-19 vaccines that protect against Ómicron